495 Trial of SNX281, a systemically delivered small molecule STING agonist, in solid tumors and lymphomas

• Judy Wang,
• Gerald Falchook,
• Johanna Bendell,
• Meghana Kulkarni,
• Melissa Johnson,
• Salah Nabhan,
• Peter Sandy,
• Ololade Dosunmu,
• Humphrey Gardner

Affiliations

Judy Wang

1 Vascular Surgery, Northern Hospital, Epping, Victoria, Australia

Gerald Falchook

Aff111 SCRI at HealthONE Denver CO USA

Johanna Bendell

Sarah Cannon Research Institute, Tennessee Oncology, Nashville, Tennessee, USA

Meghana Kulkarni

1 BURST Research Collaborative, BURST (British Urology Researchers in Surgical Training) Research Collaborative, London, UK

Melissa Johnson

3Sarah Cannon Research Institute, Nashville, TN, USA

Salah Nabhan

3Stingthera, Boston, MA, USA

Peter Sandy

3Stingthera, Boston, MA, USA

Ololade Dosunmu

4Sarah Cannon Development Innovations, Nashville, TN, USA

Humphrey Gardner

3Stingthera, Boston, MA, USA